Role of Folate Antagonists in the Treatment of Methicillin-Resistant Staphylococcus aureus Infection
The DOI matches its Crossref record; 115 of the 115 references it cites were found in a registry or an index.
Abstract
Methicillin-resistant Staphylococcus aureus (MRSA) infection has reached epidemic proportions, and therapeutic options are limited because these strains are often multidrug resistant. However, the new strains of community-acquired MRSA show decreased resistance to trimethoprim-sulfamethoxazole. Clinical and experimental reports show a mixture of successes and failures with trimethoprim-sulfamethoxazole treatment. A reason for failure might be the amount of thymidine released from damaged host tissues and bacteria, a concept strengthened by the fact that S. aureus thermonuclease releases thymidine from DNA. Thus, success or failure with trimethoprim-sulfamethoxazole may well depend on the amount of tissue damage and organism burden, rather than acquisition of a resistance gene. Clinical trials and experimental animal studies show high failure rates, perhaps because of released thymidine. The use of trimethoprim-sulfamethoxazole for community-acquired MRSA infection should not be endorsed without further research.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The efficacy of trimethoprimsulfamethoxazole and other folate antagonists may be attenuated by thymidine release from damaged host cells (eg, at sites of tissue damage such as abscesses).166”
Citations
Cites
Infectious Diseases Society of America
Enders, J. F. (1969) · Journal of Infectious Diseases · doi:10.1093/infdis/119.3.317 · Cited by 3,286
Methicillin-Resistant S. aureus Infections among Patients in the Emergency Department
Moran, G. J., Krishnadasan, A., Gorwitz, R. J., Fosheim, G. E., McDougal, L. K., Carey, R. B., & Talan, D. A. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055356 · Cited by 2,285 · cited 1×
“Thus, TMP-SMZ has been suggested for treatment of MRSA infection [13, 18, 19, 26, 27] because TMP-SMZ is inexpensive, is well tolerated, and penetrates well into tissues.”
BackgroundCosgrove, S. E., Sakoulas, G., Perencevich, E. N., Schwaber, M. J., Karchmer, A. W., & Carmeli, Y. (2003) · Clinical Infectious Diseases · doi:10.1086/345476 · Cited by 1,964
Practice Guidelines for the Diagnosis and Management of Skin and Soft-Tissue Infections
Stevens, D. L., Bisno, A. L., Chambers, H. F., Everett, E. D., Dellinger, P., Goldstein, E. J. C., Gorbach, S. L., Hirschmann, J. V., Kaplan, E. L., Montoya, J. G., et al. (2005) · Clinical Infectious Diseases · doi:10.1086/497143 · Cited by 1,602 · cited 1×
“Thus, TMP-SMZ has been suggested for treatment of MRSA infection [13, 18, 19, 26, 27] because TMP-SMZ is inexpensive, is well tolerated, and penetrates well into tissues.”
BackgroundSelf-citationProctor, R. A., von Eiff, C., Kahl, B. C., Becker, K., McNamara, P., Herrmann, M., & Peters, G. (2006) · Nature Reviews Microbiology · doi:10.1038/nrmicro1384 · Cited by 1,175
Self-citationEmergence of Vancomycin Resistance in Staphylococcus aureus
Smith, T. L., Pearson, M. L., Wilcox, K. R., Cruz, C., Lancaster, M. V., Robinson-Dunn, B., Tenover, F. C., Zervos, M. J., Band, J. D., White, E., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199902183400701 · Cited by 1,088
Hidayat, L. K., Hsu, D. I., Quist, R., Shriner, K. A., & Wong-Beringer, A. (2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.19.2138 · Cited by 860
Sakoulas, G., Moise-Broder, P. A., Schentag, J., Forrest, A., Moellering, R. C., & Eliopoulos, G. M. (2004) · Journal of Clinical Microbiology · doi:10.1128/jcm.42.6.2398-2402.2004 · Cited by 836
The benefit of appropriate empirical antibiotic treatment in patients with bloodstream infection
Leibovici, Shraga, Drucker, Konigsberger, Samra, Pitlik, & Pitlik (1998) · Journal of Internal Medicine · doi:10.1046/j.1365-2796.1998.00379.x · Cited by 685
Levine, D. P., Fromm, B. S., & Reddy, B. R. (1991) · Annals of Internal Medicine · doi:10.7326/0003-4819-115-9-674 · Cited by 577
Chang, F.-Y., Peacock, J. E., Musher, D. M., Triplett, P., MacDonald, B. B., Mylotte, J. M., O’Donnell, A., Wagener, M. M., & Yu, V. L. (2003) · Medicine · doi:10.1097/01.md.0000091184.93122.09 · Cited by 530
Resistance to Trimethoprim-Sulfamethoxazole
Eliopoulos, G. M., & Huovinen, P. (2001) · Clinical Infectious Diseases · doi:10.1086/320532 · Cited by 500 · cited 3×
“Trimethoprim is a tetrahydrofolate reductase inhibitor that, when added to sulfamethoxazole, provides a second step block in the folate biosynthetic pathway [46] (figure 1).”
BackgroundMurayama, K. M. (2007) · Cited by 477
Tenover, F. C., & Moellering, R. C. (2007) · Clinical Infectious Diseases · doi:10.1086/513203 · Cited by 452 · cited 1×
“aureus isolates [28, 38], resistance to TMP-SMZ has decreased in most populations over time.”
BackgroundThe Economic Impact of Staphylococcus aureus Infection in New York City Hospitals
Rubin, R. J., Harrington, C. A., Poon, A., Dietrich, K., Greene, J. A., & Moiduddin, A. (1999) · Emerging Infectious Diseases · doi:10.3201/eid0501.990102 · Cited by 445
Gemmell, C. G., Edwards, D. I., Fraise, A. P., Gould, F. K., Ridgway, G. L., & Warren, R. E. (2006) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkl017 · Cited by 439
Community-Associated MRSA — Resistance and Virulence Converge
Chambers, H. F. (2005) · New England Journal of Medicine · doi:10.1056/nejme058023 · Cited by 423
Gonzalez, C., Rubio, M., Romero-Vivas, J., Gonzalez, M., & Picazo, J. J. (1999) · Clinical Infectious Diseases · doi:10.1086/313440 · Cited by 407
Markowitz, N., Quinn, E. L., & Saravolatz, L. D. (1992) · Annals of Internal Medicine · doi:10.7326/0003-4819-117-5-390 · Cited by 343 · cited 2×
“There is, to our knowledge, only 1 randomized, prospective trial comparing TMP-SMZ with another drug—specifically, vancomycin [47].”
BackgroundNoskin, G. A., Rubin, R. J., Schentag, J. J., Kluytmans, J., Hedblom, E. C., Smulders, M., Lapetina, E., & Gemmen, E. (2005) · Archives of Internal Medicine · doi:10.1001/archinte.165.15.1756 · Cited by 299 · cited 1×
“than did inpatients without this infection [8].”
Harbarth, S., Rutschmann, O., Sudre, P., & Pittet, D. (1998) · Archives of Internal Medicine · doi:10.1001/archinte.158.2.182 · Cited by 267
von Eiff, C., Bettin, D., Proctor, R. A., Rolauffs, B., Lindner, N., Winkelmann, W., & Peters, G. (1997) · Clinical Infectious Diseases · doi:10.1086/516962 · Cited by 247 · cited 1×
“, osteomyelitis [110], prosthetic device infection [111], and SSTI [104, 112]), the development of SCVs would be an unwelcome adverse effect, because these organisms are difficult to treat [104].”
BackgroundSelf-citationMiller, L. G., Remington, F. P., Bayer, A. S., Diep, B., Tan, N., Bharadwa, K., Tsui, J., Perlroth, J., Shay, A., Tagudar, G., et al. (2007) · Clinical Infectious Diseases · doi:10.1086/511033 · Cited by 246
Moise, P. A., Sakoulas, G., Forrest, A., & Schentag, J. J. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00939-06 · Cited by 225 · cited 1×
“comycin [33], which is felt to be an important consideration”
BackgroundStructure and function of the dihydropteroate synthase from staphylococcus aureus
Hampele, I. C., D’Arcy, A., Dale, G. E., Kostrewa, D., Nielsen, J., Oefner, C., Page, M. G. P., Schönfeld, H.-J., Stüber, D., & Then, R. L. (1997) · Journal of Molecular Biology · doi:10.1006/jmbi.1997.0944 · Cited by 201
von Eiff, C., Becker, K., Metze, D., Lubritz, G., Hockmann, J., Schwarz, T., & Peters, G. (2001) · Clinical Infectious Diseases · doi:10.1086/320519 · Cited by 190 · cited 7×
“Because staphylococcal SCVs have been found in situations in which TMP-SMZ treatment has been recommended (e.g., osteomyelitis [110], prosthetic device infection [111], and SSTI [104] [112]), the development of SCVs would be an unwelcome adverse effect, because these organisms are difficult to treat [104].”
BackgroundInfluentialAntimicrobial drugs for treating methicillin-resistant Staphylococcus aureus colonization
Loeb, M. B., Main, C., Eady, A., & Walkers-Dilks, C. (2003) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003340 · Cited by 189
Mohr, J. F., & Murray, B. E. (2007) · Clinical Infectious Diseases · doi:10.1086/518451 · Cited by 185 · cited 1×
“The value of TMP-SMZ for MRSA infection takes on added dimensions because the use of vancomycin for treatment of MRSA is now a topic of spirited debate [28, 31].”
BackgroundKahl, B. C., Duebbers, A., Lubritz, G., Haeberle, J., Koch, H. G., Ritzerfeld, B., Reilly, M., Harms, E., Proctor, R. A., Herrmann, M., et al. (2003) · Journal of Clinical Microbiology · doi:10.1128/jcm.41.9.4424-4427.2003 · Cited by 175 · cited 7×
“Because staphylococcal SCVs have been found in situations in which TMP-SMZ treatment has been recommended (e.g., osteomyelitis [110], prosthetic device infection [111], and SSTI [104] [112]), the development of SCVs would be an unwelcome adverse effect, because these organisms are difficult to treat [104].”
BackgroundInfluentialSelf-citationDale, G. E., Broger, C., D' Arcy, A., Hartman, P. G., DeHoogt, R., Jolidon, S., Kompis, I., Labhardt, A. M., Langen, H., Locher, H., et al. (1997) · Journal of Molecular Biology · doi:10.1006/jmbi.1996.0770 · Cited by 175 · cited 2×
“Blocking folate metabolism at 2 sites decreased the emergence of resistance [44, 46].”
BackgroundBerg, T., Firth, N., Apisiridej, S., Hettiaratchi, A., Leelaporn, A., & Skurray, R. A. (1998) · Journal of Bacteriology · doi:10.1128/jb.180.17.4350-4359.1998 · Cited by 174
Counterpoint: Vancomycin and Staphylococcus aureus--An Antibiotic Enters Obsolescence
Deresinski, S. (2007) · Clinical Infectious Diseases · doi:10.1086/518452 · Cited by 173 · cited 2×
“aureus isolates [28, 38], resistance to TMP-SMZ has decreased in most populations over time.”
BackgroundHenke, M. O., & Ratjen, F. (2007) · Paediatric Respiratory Reviews · doi:10.1016/j.prrv.2007.02.009 · Cited by 168 · cited 1×
“” A major component of pus is polymerized DNA, released from inflammatory cells and injured tissues [75].”
BackgroundLong-term Survival Following Bacteremia or Fungemia
Leibovici, L. (1995) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1995.03530100047033 · Cited by 166
Iyer, S., & Jones, D. H. (2004) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2003.12.043 · Cited by 165 · cited 1×
“In contrast, morerecent reports have shown high rates of susceptibility among MRSA strains: 73% [51], 85% [14], 91% [52], 92% [53], 95% [24], and 98% [54].”
BackgroundDrew, R. H. (2000) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/46.5.775 · Cited by 165
Besier, S., Smaczny, C., von Mallinckrodt, C., Krahl, A., Ackermann, H., Brade, V., & Wichelhaus, T. A. (2007) · Journal of Clinical Microbiology · doi:10.1128/jcm.01510-06 · Cited by 164 · cited 1×
“In clinical studies of patients with cystic fibrosis, presence of staphylococcal SCVs are common [103, 108, 109] and are associated with more-progressive disease [103, 108, 109].”
BackgroundStein, A., Bataille, J. F., Drancourt, M., Curvale, G., Argenson, J., Groulier, P., & Raoult, D. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.12.3086 · Cited by 150 · cited 1×
“[88] treated orthopedic device–associated infection in 39 patients with TMP-SMZ and late device removal (for hips and knees, 6 months) unless joint instability occurred earlier.”
Sakoulas, G., Gold, H. S., Cohen, R. A., Venkataraman, L., Moellering, R. C., & Eliopoulos, G. M. (2006) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkl030 · Cited by 149
Miller, L. G., Quan, C., Shay, A., Mostafaie, K., Bharadwa, K., Tan, N., Matayoshi, K., Cronin, J., Tan, J., Tagudar, G., et al. (2007) · Clinical Infectious Diseases · doi:10.1086/511041 · Cited by 144
Szumowski, J. D., Cohen, D. E., Kanaya, F., & Mayer, K. H. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01244-06 · Cited by 136 · cited 1×
“data [23], the results may be most pertinent for the current outbreak of CA-MRSA.”
ResultEmergence of trimethoprim-sulfamethoxazole resistance in the AIDS era.
Martin, J. N., Rose, D. A., Hadley, W. K., Perdreau‐Remington, F., Lam, P. K., & Gerberding, J. L. (1999) · The Journal of Infectious Diseases · doi:10.1086/315132 · Cited by 126 · cited 1×
“aureus in HIV-infected patients receiving TMP-SMZ prophylaxis [56].”
BackgroundFortún, J., Navas, E., Martínez‐Beltrán, J., Pérez‐Molina, J., Martín‐Dávila, P., Guerrero, A., & Moreno, S. (2001) · Clinical Infectious Diseases · doi:10.1086/320869 · Cited by 126
Vancomycin treatment failures in Staphylococcus aureus lower respiratory tract infections
Moise, P. A., & Schentag, J. J. (2000) · International Journal of Antimicrobial Agents · doi:10.1016/s0924-8579(00)00303-4 · Cited by 118
MacLeod, C. M. (1940) · The Journal of Experimental Medicine · doi:10.1084/jem.72.3.217 · Cited by 117 · cited 2×
“MacLeod [40] found that inhibitory substances could be released from a large bacterial inoculum and from mammalian tissues by “autolysis.”
BackgroundResultEmerging Options for Treatment of Invasive, Multidrug‐Resistant Staphylococcus aureus Infections
Drew, R. H. (2007) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.27.2.227 · Cited by 116
Fedler, K. A., Biedenbach, D. J., & Jones, R. N. (2006) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2006.07.003 · Cited by 106
Tsuji, B. T., Rybak, M. J., Cheung, C. M., Amjad, M., & Kaatz, G. W. (2007) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2006.10.021 · Cited by 105 · cited 2×
“This may be attributable to increased susceptibility of CA-MRSA strains [24, 54], changes limited to local susceptibility patterns, or decreased use of TMP-SMZ [53].”
BackgroundBesier, S., Ludwig, A., Ohlsen, K., Brade, V., & Wichelhaus, T. A. (2007) · International Journal of Medical Microbiology · doi:10.1016/j.ijmm.2007.02.003 · Cited by 94 · cited 1×
“In clinical studies of patients with cystic fibrosis, presence of staphylococcal SCVs are common [103, 108, 109] and are associated with more-progressive disease [103, 108, 109].”
BackgroundGrim, S. A., Rapp, R. P., Martin, C. A., & Evans, M. E. (2005) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.25.2.253.56956 · Cited by 94 · cited 3×
“005 given alone for a comparable duration of time, which is consistent with the agents being synergistic [13].”
BackgroundBactericidal activity of orally available agents against methicillin-resistant Staphylococcus aureus
Kaka, A. S., Rueda, A. M., Shelburne, S. A., Hultén, K. G., Hamill, R. J., & Musher, D. M. (2006) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkl283 · Cited by 94
Antimicrobial Resistance in Staphylococcus aureus in Australian Teaching Hospitals, 1989-1999
Nimmo, G. R., Bell, J. M., Mitchell, D., Gosbell, I. B., Pearman, J. W., & Turnidge, J. D. (2003) · Microbial Drug Resistance · doi:10.1089/107662903765826741 · Cited by 85 · cited 1×
“Three longitudinal studies revealed a substantial decrease in resistance over time: 16% [55], 59% [51], and 61% [53] decreases in resistance.”
BackgroundTrimethoprim/Sulfamethoxazole for Treatment of Severe Staphylococcus aureus Infections
Adra, M., & Lawrence, K. R. (2004) · Annals of Pharmacotherapy · doi:10.1345/aph.1d156 · Cited by 85 · cited 2×
“A review by Adra and Lawrence [19] emphasizes TMP-SMZ efficacy with a low”
BackgroundEiff, C. V., Vaudaux, P., Kahl, B. C., Lew, D., Emler, S., Schmidt, A., Peters, G., & Proctor, R. A. (1999) · Clinical Infectious Diseases · doi:10.1086/520462 · Cited by 82 · cited 1×
“, osteomyelitis [110], prosthetic device infection [111], and SSTI [104, 112]), the development of SCVs would be an unwelcome adverse effect, because these organisms are difficult to treat [104].”
BackgroundSelf-citationJohnson, L. B., Almoujahed, M. O., Ilg, K., Maolood, L., & Khatib, R. (2003) · Scandinavian Journal of Infectious Diseases · doi:10.1080/00365540310016682 · Cited by 81
Koo, S. P., Bayer, A. S., Sahl, H. G., Proctor, R. A., & Yeaman, M. R. (1996) · Infection and Immunity · doi:10.1128/iai.64.3.1070-1074.1996 · Cited by 80 · cited 1×
“Staphylococcal SCVs are more resistant to host cationic peptides [105, 106], other host defenses because of their intracellular location [104], and multiple antibiotics [104].”
BackgroundSelf-citationBush, K., Heep, M., Macielag, M. J., & Noel, G. J. (2007) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.16.4.419 · Cited by 75 · cited 1×
“Entrance of ceftobiprole, an anti-MRSA b-lactam [114], will bring another variable to the therapeutic equation, because b-lactams have consistently outperformed folate antagonists.”
BackgroundRetrospective Evaluation of Therapies for Staphylococcus aureus Endocarditis
Gentry, C. A., Rodvold, K. A., Novak, R. M., Hershow, R. C., & Naderer, O. J. (1997) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/j.1875-9114.1997.tb03788.x · Cited by 72
Treatment approaches for community-acquired methicillin-resistant Staphylococcus aureus infections
Ellis, M. W., & Lewis, J. S. (2005) · Current Opinion in Infectious Diseases · doi:10.1097/01.qco.0000186850.54040.fc · Cited by 70
Chen, A. E., Goldstein, M., Carroll, K., Song, X., Perl, T. M., & Siberry, G. K. (2006) · Pediatric Emergency Care · doi:10.1097/01.pec.0000236832.23947.a0 · Cited by 64 · cited 2×
“This may be attributable to increased susceptibility of CA-MRSA strains [24, 54], changes limited to local susceptibility patterns, or decreased use of TMP-SMZ [53].”
BackgroundNorden, C. W., & Keleti, E. (1980) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.17.4.591 · Cited by 63 · cited 1×
“In a rabbit osteomyelitis model [84], infection was established for 14 days before administration of trimethoprim and rifampin, individually or in combination.”
BackgroundALDRIN POISONING IN INDUSTRIAL WORKERS
Weir, D. M. (1964) · The Lancet · doi:10.1016/s0140-6736(64)92864-8 · Cited by 62
Pneumatoceles in postpneumonic empyema: an algorithmic approach
İmamoğlu, M., Çay, A., Koşucu, P., Özdemir, O., Çobanoğlu, Ü., Orhan, F., Akyol, A., & Sarıhan, H. (2005) · Journal of Pediatric Surgery · doi:10.1016/j.jpedsurg.2005.03.048 · Cited by 61 · cited 2×
“When pneumatocoels are found in the lung, a thickened wall that does not collapse in persistent pneumatocoels predicts antibiotic failure [91].”
BackgroundSamuelsen, Ø., Haukland, H. H., Kahl, B. C., von Eiff, C., Proctor, R. A., Ulvatne, H., Sandvik, K., & Vorland, L. H. (2005) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dki385 · Cited by 58 · cited 1×
“Staphylococcal SCVs are more resistant to host cationic peptides [105, 106], other host defenses because of their intracellular location [104], and multiple antibiotics [104].”
BackgroundSelf-citationEffect of thymidine on activity of trimethoprim and sulphamethoxazole.
Stokes, A., & LACEY, R. W. (1978) · Journal of Clinical Pathology · doi:10.1136/jcp.31.2.165 · Cited by 55 · cited 1×
“Thymidine antagonizes the antistaphylococcal effects of both trimethoprim and sulfamethoxazole [76, 77] because it can be taken up via NupC and bypasses the metabolic blockades caused by TMP-SMZ (figure 1).”
BackgroundGórgolas, M., Avilés, P., Verdejo, C., & Guerrero, M. L. F. (1995) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.39.4.953 · Cited by 53 · cited 1×
“In contrast, when TMP-SMZ treatment was started 24 h after challenge with heterogeneous MRSA or MSSA in a rabbit model of endocarditis [83], 0% of vegetations were sterilized, with 84% mortality at day 3.”
MethodReversal of activity of trimethoprim against Gram-positive cocci by thymidine, thymine and ‘folates’
Hamilton-Miller, J. M. T. (1988) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/22.1.35 · Cited by 49 · cited 1×
“Thymidine antagonizes the antistaphylococcal effects of both trimethoprim and sulfamethoxazole [76, 77] because it can be taken up via NupC and bypasses the metabolic blockades caused by TMP-SMZ (figure 1).”
BackgroundChatterjee, I., Herrmann, M., Proctor, R. A., Peters, G., & Kahl, B. C. (2007) · Journal of Bacteriology · doi:10.1128/jb.01444-06 · Cited by 48 · cited 1×
“In addition, SCVs are better able to survive under starvation conditions [107].”
BackgroundSelf-citationStaphylococcal Septicemia Treated with Methicillin
Allen, J. D., Roberts, C. E., & Kirby, W. (1962) · New England Journal of Medicine · doi:10.1056/nejm196201182660302 · Cited by 47
Antibacterial resistance and their genetic location in MRSA isolated in Kuwait hospitals, 1994-2004
Udo, E. E., Al‐Sweih, N., Mokaddas, E. M., Johny, M., Dhar, R., Gomaa, H. H. A., Al‐Obaid, I., & Rotimi, V. O. (2006) · BMC Infectious Diseases · doi:10.1186/1471-2334-6-168 · Cited by 45 · cited 2×
“In contrast, morerecent reports have shown high rates of susceptibility among MRSA strains: 73% [51], 85% [14], 91% [52], 92% [53], 95% [24], and 98% [54].”
BackgroundElwell, L. P., Wilson, H. R., Knick, V. B., & Keith, B. R. (1986) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.29.6.1092 · Cited by 43 · cited 1×
“586 • CID 2008:46 (15 February) • CLINICAL PRACTICE opment of abscesses [22].”
BackgroundYeldandi, V., Strodtman, R., & Lentino, J. R. (1988) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/22.6.873 · Cited by 42
Giordano, P. A., Elston, D., Akinlade, B. K., Weber, K., Notario, G. F., Busman, T. A., Cifaldi, M., & Nilius, A. M. (2006) · Current Medical Research and Opinion · doi:10.1185/030079906x148355 · Cited by 39 · cited 7×
“Because staphylococcal SCVs have been found in situations in which TMP-SMZ treatment has been recommended (e.g., osteomyelitis [110], prosthetic device infection [111], and SSTI [104] [112]), the development of SCVs would be an unwelcome adverse effect, because these organisms are difficult to treat [104].”
BackgroundInfluentialRandrianirina, F., Soares, J.-L., Ratsima, E. H., Carod, J.-F., Combe, P., Grosjean, P., Richard, V., & Talarmin, A. (2007) · Annals of Clinical Microbiology and Antimicrobials · doi:10.1186/1476-0711-6-5 · Cited by 39 · cited 1×
“In contrast, morerecent reports have shown high rates of susceptibility among MRSA strains: 73% [51], 85% [14], 91% [52], 92% [53], 95% [24], and 98% [54].”
BackgroundThymidyl biosynthesis enzymes as antibiotic targets
Chernyshev, A., Fleischmann, T., & Kohen, A. (2007) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-006-0763-1 · Cited by 38 · cited 2×
“Sulfonamides inhibit dihydropteroate synthase, which blocks folate biosynthesis [39].”
BackgroundSTUDIES ON THE MECHANISM OF THE ACTION OF SULFANILAMIDE
Lockwood, J. S., & Lynch, H. M. (1940) · JAMA · doi:10.1001/jama.1940.02810110001001 · Cited by 38
Nature of the Bactericidal Action of Sulfonamides and Trimethoprim, Alone and in Combination
Then, R. L., & Angehrn, P. (1973) · The Journal of Infectious Diseases · doi:10.1093/infdis/128.supplement_3.s498 · Cited by 38
Variability in SCC mecN1 spreading among injection drug users in Zurich, Switzerland
Ender, M., Berger‐Bächi, B., & Holmes, N. (2007) · BMC Microbiology · doi:10.1186/1471-2180-7-62 · Cited by 37 · cited 1×
“Of concern is the recent linkage of the gene for high-level trimethoprim resistance with SCCmecN1, which was found in an epidemic of CA-MRSA strains [58].”
BackgroundJones, R. N., Sader, H. S., Fritsche, T. R., & Pottumarthy, S. (2006) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2006.06.011 · Cited by 35 · cited 1×
“aureus (MSSA) strains were found to be susceptible to TMP-SMZ [57].”
BackgroundThe Identification of Staphylococci in Clinical and Food Microbiology Laboratories
Sperber, W. H. (1977) · CRC Critical Reviews in Clinical Laboratory Sciences · doi:10.3109/10408367709151577 · Cited by 35
Co-trimoxazole–Sensitive, Methicillin-ResistantStaphylococcus aureus, Israel, 1988–1997
Bishara, J., Pitlik, S. D., Samra, Z., Levy, I., Paul, M., & Leibovici, L. (2003) · Emerging infectious diseases · doi:10.3201/eid0909.020666 · Cited by 34 · cited 3×
“This may be attributable to increased susceptibility of CA-MRSA strains [24, 54], changes limited to local susceptibility patterns, or decreased use of TMP-SMZ [53].”
BackgroundTamer, M. A., & Bray, J. D. (1982) · Clinical Pediatrics · doi:10.1177/000992288202100211 · Cited by 30
Trimethoprim-Sulfamethoxazole in The Treatment of Bacterial Endocarditis
Seligman, S. J., Madhavan, T., & Alcid, D. V. (1973) · The Journal of Infectious Diseases · doi:10.1093/infdis/128.supplement_3.s754 · Cited by 26
SULFADIAZINE; FURTHER CLINICAL STUDIES OF ITS EFFICACY AND TOXIC EFFECTS IN 460 PATIENTS
Finland, M., Peterson, O. L., & GOODWIN, R. A. (1942) · Annals of Internal Medicine · doi:10.7326/0003-4819-17-6-920 · Cited by 26
Jemni, L., Hmouda, H., & Letaief, A. O. (1994) · Clinical Infectious Diseases · doi:10.1093/clinids/19.1.202 · Cited by 25
Lachica, R. V. F. (1976) · Applied and Environmental Microbiology · doi:10.1128/aem.32.4.633-634.1976 · Cited by 25
Trimethoprim-Sulphamethoxazole Treatment in Staphylococcal Endocarditis and Gram-Negative Septicemia
Bengtsson, E., Svanbom, M., & Tunevall, G. (1974) · Scandinavian Journal of Infectious Diseases · doi:10.3109/inf.1974.6.issue-2.13 · Cited by 24
Tillett, W. S., Cambier, M. J., & Harris, W. H. (1943) · Journal of Clinical Investigation · doi:10.1172/jci101390 · Cited by 23 · cited 2×
“Favorable outcomes also occurred with staphylococcal pneumonia [70].”
BackgroundRole of linezolid in the treatment of complicated skin and soft tissue infections
Peppard, W., & Weigelt, J. A. (2006) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.4.3.357 · Cited by 22
Apellaniz, G., Valdés, M., Pérez, R., Martin, F., Soria, F., García, A. O., Gòmez, J., & Vicente, T. (1991) · Journal of Chemotherapy · doi:10.1080/1120009x.1991.11739072 · Cited by 19
Mongkolrattanothai, K., & Daum, R. S. (2005) · Current Infectious Disease Reports · doi:10.1007/s11908-005-0013-1 · Cited by 19
Bujdáková, H., Klimáčková, J., Allerberger, F. J., Moravčı́ková, M., Bagová, M., Hanzen, J., Michalkova-Papajova, D., Dierich, M. P., & Kettner, M. (2000) · International Journal of Antimicrobial Agents · doi:10.1016/s0924-8579(00)00195-3 · Cited by 18
Sulfonamide-Resistant Strains of Staphylococci: Clinical Significance.
Vivino, J. J., & Spink, W. W. (1942) · Experimental Biology and Medicine · doi:10.3181/00379727-50-13790 · Cited by 18
Studies on the Mechanism of Sulfonamide Bacteriostasis, Inhibition and Resistance
Strauss, E., Dingle, J. H., & Finland, M. (1941) · The Journal of Immunology · doi:10.4049/jimmunol.42.3.331 · Cited by 17
Honda, T., Hayasaka, M., Hachiya, T., Kubo, K., Katsuyama, T., & Nagata, A. (1996) · Internal Medicine · doi:10.2169/internalmedicine.35.979 · Cited by 14
Rao, J., Qamruddin, A., Hassan, I. A., Burnie, J., & Ganner, M. (2002) · Journal of Hospital Infection · doi:10.1053/jhin.2002.1225 · Cited by 14 · cited 1×
“aureus cells [78–81], although there was 1 outbreak of infection with nuc-negative MRSA strains [82].”
BackgroundShafqat, S. H., Shah, S. A., & Seyed, S. A. (1971) · Heart · doi:10.1136/hrt.33.6.974 · Cited by 13
Vancomycin for treatment of invasive, multi-drug resistantStaphylococcus aureusinfections
Pope, S. D., & Roecker, A. M. (2007) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.8.9.1245 · Cited by 11
Spink, W. W., & Jermsta, J. (1941) · Experimental Biology and Medicine · doi:10.3181/00379727-47-13153 · Cited by 11
Chambers, H. F. “., & Hegde, S. S. (2007) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.5.3.333 · Cited by 10
Khawcharoenporn, T., & Alan, T. T. (2006) · PubMed · Cited by 9
Methicillin-Resistant Staphylococci and Their Treatment in the Intensive Care Unit
Eguia, J. M., & Chambers, H. F. “. (2003) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-2003-37915 · Cited by 9
STAPHYLOCOCCAL SEPTICÆMIA TREATED WITH M. & B. 693
O’Brien, E., & McCarthy, C. (1938) · The Lancet · doi:10.1016/s0140-6736(00)78975-6 · Cited by 7
Spink, W. W., & Vivino, J. J. (1944) · Journal of Clinical Investigation · doi:10.1172/jci101490 · Cited by 7 · cited 3×
“aureus strains that were susceptible to sulfonamides was 34%, whereas mortality for strains resistant to sulfonamides was 36% [42].”
BackgroundResultTHE SULFONAMIDE THERAPY OF STAPHYLOCOCCAL SEPTICEMIA
TORREY, R. G., Julianelle, L. A., & Mcnamee, H. G. (1941) · Annals of Internal Medicine · doi:10.7326/0003-4819-15-3-431 · Cited by 6 · cited 1×
“[71] reviewed the data for 1933–1941 on the outcomes of patients with bacteremia.”
BackgroundCHEMOTHERAPY AND CHEMOSEROTHERAPY OF STAPHYLOCOCCIC INFECTIONS
KOLMER, J. A. (1942) · Archives of Internal Medicine · doi:10.1001/archinte.1942.00200160087007 · Cited by 6 · cited 1×
“In models of bacteremia in mice and rabbits [64], sulfonamides were initiated at 4 h in mice and 3 days in rabbits.”
Carroll, G., Kappel, L., Jones, L., Gallagher, F. W., & DiRocco, F. W. (1940) · Southern Medical Journal · doi:10.1097/00007611-194001000-00023 · Cited by 5
The treatment of acute staphylococcic infections with sulfamethylthiazol
Weisman, D., & Russell, H. K. (1940) · The Journal of Pediatrics · doi:10.1016/s0022-3476(40)80080-2 · Cited by 4
THE PRODUCTION OF p‐AMINOBENZOIC ACID BY STAPHYLOCOCCUS AUREUS, MADE RESISTANT TO SULPHONAMIDES
Moss, F., & Lemberg, R. (1950) · Immunology and Cell Biology · doi:10.1038/icb.1950.69 · Cited by 3
Beling, C. A., & Abel, A. R. (1940) · The American Journal of Surgery · doi:10.1016/s0002-9610(40)90608-0 · Cited by 3 · cited 1×
“Finally, in a series of 38 cases, treatment with sulfamethylthiazole was successful when the patients had cellulitis alone but failed when abscess was present [60].”
ResultKaplan, N. M. (2003) · Eastern Mediterranean Health Journal · doi:10.26719/2003.9.1-2.185 · Cited by 3
McDowell, B., & Cj, P. (1992) · PubMed · Cited by 3
A new treatment for furunculosis (sulfamethylthiazol)
Grulee, C. G., & Mason, J. T. (1940) · The Journal of Pediatrics · doi:10.1016/s0022-3476(40)80185-6 · Cited by 1
Staphylococcal Septicaemia Treated with Sulphadiazine
Norman, H. (1944) · BMJ · doi:10.1136/bmj.1.4335.183 · Cited by 1
Discussions on Clinical Experiences with Sulphathiazole in Therapy of Staphylococcal Infections
(1940) · Proceedings of the Royal Society of Medicine · doi:10.1177/003591574003301016 · Cited by 1
Research works printed but not linked: 11
- Khawcharoenporn, 2006, Hawaii medical journal, 65, 290
- Markowitz, 1992, Annals of Internal Medicine, 117, 390, 10.1059/0003-4819-117-5-390 · doi:10.1059/0003-4819-117-5-390
- 1939, Lancet, 2, 1065
- 1939, INTL CLINICS, 4, 1
- 1938, Lancet, 2, 1233
- 1938, Lancet, 2, 1232
- TORREY, 1941, Annals of Internal Medicine, 15, 431, 10.1059/0003-4819-15-3-431 · doi:10.1059/0003-4819-15-3-431
- 1939, Lancet, 1, 756
- McDowell, 1991, Clinical laboratory science : journal of the American Society for Medical Technology, 4, 299
- FINLAND, 1942, Annals of Internal Medicine, 17, 920, 10.1059/0003-4819-17-6-920 · doi:10.1059/0003-4819-17-6-920
- Levine, 1991, Annals of Internal Medicine, 115, 674, 10.1059/0003-4819-115-9-674 · doi:10.1059/0003-4819-115-9-674
Cited by
Liu, C., Bayer, A., Cosgrove, S. E., Daum, R. S., Fridkin, S. K., Gorwitz, R. J., Kaplan, S. L., Karchmer, A. W., Levine, D. P., Murray, B. E., et al. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/ciq146 · Cited by 4,191
Baddour, L. M., Wilson, W. R., Bayer, A. S., Fowler, V. G., Tleyjeh, I. M., Rybak, M. J., Barsic, B., Lockhart, P. B., Gewitz, M. H., Levison, M. E., et al. (2015) · Circulation · doi:10.1161/cir.0000000000000296 · Cited by 3,232
“ated by thymidine release from damaged host cells (eg, at sites of tissue damage such as abscesses).(166) In an in vitro study,(167)”
BackgroundDavid, M. Z., & Daum, R. S. (2010) · Clinical Microbiology Reviews · doi:10.1128/cmr.00081-09 · Cited by 1,972
Community-associated meticillin-resistant Staphylococcus aureus
DeLeo, F. R., Otto, M., Kreiswirth, B. N., & Chambers, H. F. (2010) · The Lancet · doi:10.1016/s0140-6736(09)61999-1 · Cited by 1,506
Nanotechnology as a therapeutic tool to combat microbial resistance
Pelgrift, R. Y., & Friedman, A. J. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.07.011 · Cited by 1,432
Metadata
- Authors
- Goldstein, E. J. C., & Proctor, R. A.
- Affiliations
- University of Wisconsin–Madison (US)
- Corresponding author
- Proctor, R. A.
- ORCID
- Proctor, R. A.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2008-02-15
- Volume
- 46
- Issue
- 4
- Pages
- 584-593
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2087260740
- Semantic Scholar
- f78fb0266126827966c2fc1286d2a500166b4fb5
- Cited by
- 138
- References
- 115
- Citations by year
- 2026: 5 · 2025: 1 · 2024: 5 · 2023: 4 · 2022: 3 · 2021: 2 · 2020: 5 · 2019: 3 · 2018: 6 · 2017: 6 · 2016: 2 · 2015: 5 · 2014: 14 · 2013: 7 · 2012: 11
- FWCI
- 2.28
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Infectious Diseases (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antimicrobial Resistance in Staphylococcus
- Health Sciences › Medicine › Infectious Diseases › Antibiotic Use and Resistance
- Health Sciences › Medicine › Infectious Diseases › Streptococcal Infections and Treatments
- Keywords
- methicillin-resistant Staphylococcus aureus, trimethoprim-sulfamethoxazole, antifolate, thermonuclease, community-acquired MRSA, multidrug resistance, antibiotic treatment failure, tissue damage
- MeSH terms
- Animals, Anti-Infective Agents, Humans, Staphylococcal Infections, Staphylococcus aureus, Trimethoprim, Sulfamethoxazole Drug Combination, Methicillin Resistance, Community-Acquired Infections
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.